Skip to content

Study of humectant containing oat kernel oil for topical treatment of xeroderma in children

Study of humectant containing oat kernel oil for topical treatment of xeroderma in children

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200058893
Enrollment
Unknown
Registered
2022-04-18
Start date
2022-06-01
Completion date
Unknown
Last updated
2024-01-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Xeroderma

Interventions

Soothing care cream group:Soothing care cream
Silicon cream group:Silicon cream

Sponsors

Beijing Friendship Hospital, Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
3 Years to 12 Years

Inclusion criteria

Inclusion criteria: 1. Ages 3 to 12; Men and women; 2. Clinical diagnosis of xeroderma, and bilateral limb skin lesions symmetrical distribution; 3. Xerosis Severity Scale (XSS)1~4 points ; 4. Visual Analogue Scale (VAS) 1 to 6 points; 5. Can use research products and follow up regularly as required; 6. Subject and/or guardian agree and sign written informed consent.

Exclusion criteria

Exclusion criteria: 1. People who are allergic to any component of the product for research; 2. Local rash with virus, bacteria or fungus infection; 3. Severe liver and kidney disease, blood system disease, autoimmune disease, chronic severe infection, diabetes, psychosis, etc; 4. Patients with malignant tumors or other serious diseases that may affect the correct evaluation of curative effect; 5. The withdrawal time of topical drugs such as glucocorticoids, calcineurin inhibitors, retinoic acid preparations, and traditional Chinese medicine was less than 2 weeks; The withdrawal time of glucocorticoid, immunosuppressant (Tripterygium wilfordii, etc.), retinoic acid drugs, diuretics and other systems was less than 4 weeks; Phototherapy was stopped for less than 4 weeks; 6. Other reasons considered unsuitable by the researcher.

Design outcomes

Primary

MeasureTime frame
Specified Symptom Sum Score;

Countries

China

Contacts

Public ContactLinfeng Li

Beijing Friendship Hospital, Capital Medical University

zoonli@sina.com+86 13693620186

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026